Results 61 to 70 of about 2,329 (147)

Effects of Selective Sphingosine‐1‐Phosphate Receptor 1 Agonist, TRV045, on Evoked Pain Tests: An Exploratory, Four‐Way Cross‐Over Study in Healthy Volunteers

European Journal of Pain, Volume 30, Issue 6, July 2026.
ABSTRACT Introduction Preclinical evidence suggests that dysregulation of the ceramide‐sphingosine‐1‐phosphate (S1P) axis may have analgesic properties. However, currently approved S1PR1 modulators such as fingolimod are hindered for this indication as they induce lymphopenia.
Wouter A. Bakker, P. Eijsvogel, Erica S. Klaassen, Jessica Kim, Ruihua Chen, Mark A. Demitrack, Albert Dahan, Marieke Niesters, Hemme J. Hijma, Geert Jan Groeneveld   +9 more
wiley   +1 more source

CD8+ Tissue‐Resident Memory T Cells in Health and Disease

MedComm, Volume 7, Issue 7, July 2026.
CD8+ TRM cells are at the center of immunity, mediating potent local innate and adaptive immune responses. While TRM cells mediate protective immunity against infections and tumors, they also contribute to pathological inflammation in autoimmune conditions.
Yu‐Han Ai, Ting‐Ting Xu, Sen Lin, Meng‐Yu Xiao, Yun‐Xia Lin, Hao‐Wen Ma, Yue‐Yang Liu, Yao‐Jie Wang, Lu‐Ning Yin, Mei Huang, Yong‐Da Liu, Chao Zhu, Xiao‐Ting Zhu, Ji‐Hang Yuan   +13 more
wiley   +1 more source

Systematic Review of Malignancy Risk with Biologic, Advanced Small-Molecule, and Thiopurine Therapies for Inflammatory Bowel Disease

Gastrointestinal Disorders
Patients with inflammatory bowel disease (IBD) often require long-term immunosuppressive or advanced therapy, raising concerns about treatment-associated malignancy risk.
Gurleen Kaur, Rahul Jain, Palak Grover, Zarqa Yasin, Karanbir Singh, Bipneet Singh   +5 more
doaj   +1 more source

Comparative efficacy of ofatumumab oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons

Therapeutic Advances in Neurological Disorders
Background: Evidence from network meta-analyses (NMAs) and real-world propensity score (PS) analyses suggest monoclonal antibodies (mAbs) offer a therapeutic advantage over currently available oral therapies and, therefore, warrant consideration as a ...
Nicholas Riley, Christopher Drudge, Morag Nelson, Anja Haltner, Michael Barnett, Simon Broadley, Helmut Butzkueven, Pamela McCombe, Anneke Van der Walt, Erin O. Y. Wong, Martin Merschhemke, Nicholas Adlard, Rob Walker, Imtiaz A. Samjoo   +13 more
doaj   +1 more source

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background We aimed to investigate and characterise DILI due to approved therapies for inflammatory bowel disease (IBD). Methods Using the Drug‐Induced Liver Injury Network (DILIN) prospective study, we evaluated definite, highly likely, or probable DILI attributed to IBD therapies, including use for non‐IBD indications (but excluding ...
Harish Gopalakrishna, Jiezhun Gu, Yi‐Ju Li, Huiman Barnhart, Dina Halegoua‐DeMarzio, Herbert L. Bonkovsky, A. Sidney Barritt, Jean P. Molleston, Naga P. Chalasani, Marwan Ghabril   +9 more
wiley   +1 more source

The neuro‐immune interface in multiple sclerosis: From pathogenesis to therapeutic opportunities

Brain‐X, Volume 4, Issue 2, June 2026.
This review analyzes the immunopathology of multiple sclerosis (MS), focusing on the interactions between innate and adaptive immunity, glial cells, and key molecular mechanisms such as MHC, chemokines, cytokines, and the complement system. It also explores current and emerging therapeutic strategies, providing a comprehensive view of disease ...
Ruohan Wang, Mengqi Li, Xinyao Chen, Manling Lang, Qifei Cong   +4 more
wiley   +1 more source

A label‐free impedance assay in endothelial cells differentiates the activation and desensitization properties of clinical S1P1 agonists

FEBS Open Bio, 2020
Sphingosine‐1 phosphate receptor‐1 (S1P1) activation maintains endothelial barrier integrity, whereas S1P1 desensitization induces peripheral blood lymphopenia.
Patrick Grailhe, Asma Boutarfa‐Madec, Philippe Beauverger, Philip Janiak, Ashfaq A. Parkar   +4 more
doaj   +1 more source

Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis

Journal of Comparative Effectiveness Research, 2023
Aim: To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) using network meta-analysis (NMA).
Imtiaz A Samjoo, Christopher Drudge, Sarah Walsh, Santosh Tiwari, Roisin Brennan, Ibolya Boer, Dieter A Haring, Luisa Klotz, Nicholas Adlard, Judit Banhazi   +9 more
doaj   +1 more source

Cytomegalovirus Isolated to a Colon Polyp in a Patient with Ulcerative Colitis on Ozanimod: A Case Report

Case Reports in Gastroenterology
Introduction: Cytomegalovirus (CMV) infection is a notable gastrointestinal infection affecting immunocompromised patients. In the gastrointestinal tract, CMV often presents with patchy or diffuse mucosal involvement and can cause fulminant ...
Zehra Naseem, Ahmed Nadeem, Aidan J. David, Aun Muhammad, Fatima Zehra Shah, Brian M. Fung, Stephen B. Hanauer, Joseph David   +7 more
doaj   +1 more source

Clinician\u27s Guide to Using Ozanimod for the Treatment of Ulcerative Colitis.

, 2023
The emergence of advanced therapies (eg, biologics, Janus kinase inhibitors) over the past few decades has revolutionized the treatment of ulcerative colitis. However, the limitations of these therapies leave an unmet need for safer and more effective or
Rubin, David T, Chiorean, Michael V, Schreiber, Stefan, Ungaro, Ryan C, Sands, Bruce E, Blumenstein, Irina   +5 more
core   +1 more source